Results 181 to 190 of about 142,066 (310)

Interstitial lung diseases in the 2020s

open access: yesLa Presse Médicale, 2020
Dominique, Valeyre, Marc, Humbert
openaire   +3 more sources

Three‐dimensional geometric morphometric analysis of diaphragmatic dome motion in COPD patients

open access: yesThe Anatomical Record, EarlyView.
Abstract Diaphragmatic dysfunction is a hallmark of chronic obstructive pulmonary disease (COPD), especially in emphysema, where hyperinflation alters diaphragm geometry and impairs inspiratory mechanics. However, quantitative three‐dimensional (3D) assessments of diaphragmatic dome shape and motion across COPD phenotypes are limited.
José M. López‐Rey   +5 more
wiley   +1 more source

From Silicosis to Scleroderma: Erasmus Syndrome

open access: yesOpen Respiratory Archives, 2023
María Belén Noboa   +4 more
doaj   +1 more source

Interstitial lung disease induced by exogenous agents: factors governing susceptibility

open access: yes, 2001
The purpose of this review is to describe the present state of knowledge regarding host susceptibility factors that may determine the occurrence, development and severity of interstitial lung disease (ILD) caused by exogenous agents.
Kinnula, V.   +30 more
core  

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm   +2 more
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

open access: yesArthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Phase-resolved functional lung magnetic resonance imaging for evaluation of lung perfusion and ventilation in fibrosing interstitial lung diseases. [PDF]

open access: yesInsights Imaging
Ni Y   +15 more
europepmc   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy